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The involvement of nitric oxide (NO) and cyclic GMP (cGMP) in neurogenesis has been progressively unmasked over the last
decade. Phosphodiesterase 5 (PDE5) specifically degrades cGMP and is highly abundant in the mammalian brain. Inhibition of
cGMP hydrolysis by blocking PDE5 is a possible strategy to enhance the first step of neurogenesis, proliferation of neural stem
cells (NSC). In this work, we have studied the effect on cell proliferation of 3 inhibitors with different selectivity and potency for
PDE5, T0156, sildenafil, and zaprinast, using subventricular zone-(SVZ-) derived NSC cultures. We observed that a short- (6 h) or
a long-term (24 h) treatment with PDE5 inhibitors increased SVZ-derived NSC proliferation. Cell proliferation induced by PDE5
inhibitors was dependent on the activation of the mitogen-activated protein kinase (MAPK) and was abolished by inhibitors of
MAPK signaling, soluble guanylyl cyclase, and protein kinase G. Moreover, sildenafil neither activated ERK1/2 nor altered p27Kip1
levels, suggesting the involvement of pathways different from those activated by T0156 or zaprinast. In agreement with the present
results, PDE5 inhibitors may be an interesting therapeutic approach for enhancing the proliferation stage of adult neurogenesis.
1. Introduction
Neurogenesis is the biological process of generating new
neurons from progenitor cells or neural stem cells (NSC).
NSC proliferate in two main regions of the adult mammalian
brain: the subventricular zone (SVZ) of the lateral ventricles
and the subgranular zone (SGZ) of dentate gyrus of the
hippocampus. Following brain injury, such as stroke, NSC in
the endogenous niches proliferate andmigrate to the affected
brain areas where they may differentiate into neurons, but
survival is limited [1–3]. There is still a lack of knowledge
concerning the use of effective therapeutic strategies in order
to overcome the limited ability of brain self-repair following
an insult. Understanding the signaling pathways involved
in the regulation of neurogenesis is paramount in order to
enhance brain repair.
Neurogenesis is affected by several factors, including
nitric oxide (NO). NO is a free radical of particular interest
due to its cellular function as a second messenger, which
includes the regulation of NSC proliferation. Several studies
recently reported the effect of NO on the stimulation of
adult neurogenesis in the dentate gyrus and in the SVZ [4–
8]. Thus, the increase of NO levels following brain injury,
such as seizures or ischemia, has been shown to promote
proliferation of NSC and the formation of new neurons [4,
5, 8]. Two distinct pathways seem to be involved in the prolif-
erative effect of NO, the extracellular signal-regulated kinase
(ERK)/mitogen-activated protein kinase (MAPK) pathway
[5] and the soluble guanylyl cyclase (sGC)/protein kinase
G (PKG) pathway [9]. The second messenger cyclic GMP
(cGMP) is a signaling molecule whose levels are regulated
by an equilibrium between its production and removal.
cGMP is produced by sGC, which can be activated by NO.
Activation of sGC by NO leads to increased cGMP levels that
activate downstream targets, such as PKG [10, 11]. PKG is a
serine/threonine cGMP-dependent kinase that regulates the
activity of several transcription factors that control important
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processes like synaptic plasticity (reviewed by [12]). In several
conditions, such as aging, cGMP levels are decreased and
may be involved in age-related neurodegeneration, decreased
neurogenesis, and cognitive decline [13]. Similar to the
increase of cGMP production by NO, the inhibition of cGMP
hydrolysis, by targeting phosphodiesterases (PDE), could be
a strategy to increase the levels of cGMP and, consequently,
reverse these effects by stimulating neurogenesis.
PDE are ubiquitous enzymes responsible for the degrada-
tion of cyclic nucleotides, whose activity is dependent on sub-
strate, kinetic properties, and cellular and subcellular distri-
bution of the 11 known families. PDE5, 6, and 9 are considered
cGMP specific PDE,whereas PDE4, 7, and 8mainly hydrolyze
cyclic AMP (cAMP) and PDE1, 2, 3, 10, and 11 hydrolyze
both substrates (reviewed in [14]). Phosphodiesterase type
5 is specific for cGMP degradation and is present in the
mammalian brain [15, 16]. PDE5 inhibitors have been used
for the treatment of several pathologies in which an increase
in cGMP levels can be beneficial, such as erectile dysfunction
and pulmonary hypertension (reviewed by [17, 18]). The best
characterized inhibitor of PDE5 is sildenafil. Sildenafil was
first used for the treatment of erectile dysfunction. Due to
the presence of PDE5 in the lung, sildenafil is also used in
the treatment of pulmonary hypertension (reviewed by [18–
20]). Since PDE5 is also present in the central nervous system,
several works have assessed the effect of sildenafil on the
brain (reviewed by [21]). Some studies reported that sildenafil
improves learning and memory [22, 23] and also induces
neurogenesis in the SVZ and SGZ [24]. Neuronal function
recovery in adult young rats and in aged rats [25], following
stroke, has also been described after sildenafil treatment [26,
27]. Zaprinast, the first PDE5 inhibitor to be used, has been
shown to be a nonpotent and nonselective inhibitor. Sildenafil
is typically considered a PDE5 inhibitor, with an IC
50
of
approximately 4 nM, and it has been shown to inhibit PDE5 at
concentrations about 200-fold lower than the concentration
of zaprinast required to inhibit PDE5 [28]. However, it also
inhibits PDE1 and PDE6 (IC
50
values of 281 and 29 nM,
resp. [28]), indicating that sildenafil is not totally selective for
PDE5.More recently, a new compoundwas developed, T0156,
which potently inhibits PDE5 [29]. In fact, T0156 has a much
lower IC
50
for PDE5 (0.23 nM) than sildenafil (IC
50
3.6 nM).
Within this scenario, in this work we investigated the
effect of three different PDE5 inhibitors: T0156, sildenafil,
and zaprinast, on the first step of neurogenesis, by evalu-
ating proliferation of SVZ-derived NSC, and addressed the
mechanisms underlying these effects. Here we show that
T0156, sildenafil, and zaprinast increase SVZ-derived NSC
proliferation.Moreover, blockingMAPK, sGC, or PKG, inde-
pendently, results in loss of the proliferative effect of PDE5
inhibitors, pointing out to the involvement of sGC/PKG and
ERK/MAPK pathways in the stimulation of NSC prolifera-
tion by PD5 inhibition.
2. Methods
2.1. Materials. Dulbecco’s Modified Eagle’s Medium: F-
12 nutrient mixture, (D-MEM/F-12, with GlutaMAX I),
B27 supplement, trypsin-ethylenediaminetetraacetic acid
(EDTA) solution, antibiotics (10,000 units/mL penicillin,
10mg/mL streptomycin), Click-iT EdU Alexa Fluor 488
Flow Cytometry Assay kit, Click-iT EdU Alexa Fluor 594
HCS Assay kit, and StemPro Accutase cell dissociation
reagent were purchased from Invitrogen (Paisley, UK). Epi-
dermal growth factor (EGF) and basic fibroblast growth
factor (bFGF) were from PeproTech Inc. (London, UK).
The Matrix used was from Stoelting Co. (Wood Dale, IL,
USA). Bicinchoninic acid (BCA) Protein Assay kit was
from Pierce (Rockford, IL, USA). 8-bromoguanosine 3󸀠,5󸀠-
cyclic monophosphate (8-Br-cGMP), Phenylmethylsulfonyl
fluoride, orthovanadate, chymostatin, leuptin, antipain, pep-
statin A, trypan blue, Tween-20, mouse anti-𝛼-tubulin, 2-
Propanol, chloroform, andTRI Reagent were purchased from
Sigma Chemical (St Louis, MO, USA). T0156 hydrochloride,
sildenafil citrate, zaprinast, and 1𝐻-[1, 2, 4]Oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ) were obtained from Tocris Bio-
science (Bristol, UK). KT5823 was obtained from Alomone
Labs (Jerusalem, Israel) and 3-(5󸀠-Hydroxymethyl-2󸀠-furyl)-
1-benzylindazole (YC-1) from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). 1,4-diamino-2,3-dicyano-1,4-bis[2-
aminophenylthio] butadiene (U0126), rabbit anti-p27Kip1,
rabbit anti-ERK1/2, and rabbit anti-phospho-ERK1/2 were
purchased from Cell Signaling (Danvers, MA, USA). Poly-
merase chain reaction (PCR) primers were obtained from
Eurofins MWGOperon (Ebersberg, Germany) and FastStart
PCR Master Mix and Transcriptor High Fidelity cDNA
Synthesis kit were from Roche Diagnostics (Mannheim, Ger-
many). Bovine serum albumin (BSA) was from Calbiochem
(San Diego, CA, USA) and polyvinylidene difluoride mem-
branes were purchased from Millipore (Madrid, Spain).
Amersham cGMP enzyme immunoassay Biotrak System,
enhanced chemifluorescence reagent, and anti-rabbit and
anti-mouse alkaline phosphatase-conjugated antibodies were
from GE Healthcare Life Sciences (Buckinghamshire, UK).
Other reagents used in immunoblotting experiments were
purchased from Bio-Rad (Hercules, CA, USA).
2.2. Animals. C57BL/6J mice were obtained from Charles
River (Barcelona, Spain) and kept in our animal facilities with
food and water ad libitum in a 12-hour dark : light cycle. All
experiments were performed in accordancewith Institutional
and European Guidelines (86/609/EEC) for the care and use
of laboratory animals.
2.3. Subventricular Zone Cell Cultures. Neural stem cell cul-
tures were obtained from the SVZ of 0–3 postnatal day
C57BL/6J mice as previously described [30]. The fragments
of SVZ were digested in 0.025% trypsin/0.265mM EDTA,
for 15–20 minutes at 37∘C, and then mechanically dissoci-
ated. The cells were resuspended in a 37∘C D-MEM/F-12
medium with 2mM GlutaMAX-I, supplemented with 1%
B27, 1% antibiotic (10,000 units/mL penicillin, 10mg/mL
streptomycin), 10 ng/mL EGF, and 5 ng/mL bFGF, and plated
on uncoated flasks with filter cap, at a density of 100,000
cells/mL. The SVZ stem cells were grown as floating aggre-
gates in a 95% air/5% CO
2
humidified atmosphere at 37∘C,
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during 7 days. Then, the primary neurospheres were har-
vested, centrifuged, and mechanically dissociated as single
cells. Cells were replated as above and allowed to grow as
secondary neurospheres. 6-7 days later, the floating neuro-
spheres were collected, dissociated, and plated for 2-3 days
on poly-L-lysine-coated 12-well plates in the same medium
as above. In the 24 h preceding the experimental treatments,
the cells were kept with a similar medium but without growth
factors in order to ensure that the results observed following
cell treatments were not due to the effect of EGF or bFGF.
2.4. Experimental Treatments. For cell proliferation analy-
sis, the times of cell treatment with PDE5 inhibitors were
chosen based on the times used previously to evaluate cell
proliferation in SVZ-derived NSC using a NO-donor [9].
Thus, the cells were exposed for 6 h and 24 h to PDE5
inhibitors or stimulated for 24 h with the sGC activator, YC-1,
or the cGMP analogue, 8-Br-cGMP (20 𝜇M). To analyze the
phosphorylation of ERK1/2 and the levels of p27Kip1, different
times were tested and SVZ-derived NSC were treated for
2 h in the following experiments, or as indicated in the
figure legends. In both experiments, the stimuli applied were
as follows: PDE inhibitors T0156 (1 𝜇M), sildenafil (1 𝜇M),
and zaprinast (10𝜇M) or sGC activator YC-1 (20𝜇M) were
incubated alone or together with the MEK1/2 inhibitor
U0126 (1 𝜇M), the PKG inhibitor KT5823 (1 𝜇M), or the
sGC inhibitor ODQ (50 𝜇M). U0126, KT5823, and ODQ
were applied 30min before exposure to PDE5 inhibitors
and YC-1 and kept throughout the incubation period. For
determination of cGMP levels, cells were treated with T0156
(1 𝜇M), sildenafil (1 𝜇M), or zaprinast (10 𝜇M) for 6 h. All
the experiments were performed together with the respective
controls (untreated cells).
2.5. Analysis of Cell Proliferation by Flow Cytometry. SVZ-
derived neural stem cell proliferation was assessed by incor-
poration of ethynyl-2󸀠-deoxyuridine (EdU) using the Click-
iT EdU Alexa Fluor 488 Flow Cytometry Assay kit, as
previously described [31]. 10 𝜇M EdU was added to the SVZ
cultures for 6 h or 4 h before fixation, for the cells treated
for 6 h or 24 h, respectively. For fixation, cells were washed
with sterile 0.01M PBS and then sterile StemPro Accutase
cell dissociation reagent was added for 20min, at 37∘C. Cell
fixation was performed in 70% ethanol overnight, at 4∘C, as
described previously [5, 31]. Detection of EdU incorporation
was based on click chemistry, a copper catalyzed covalent
reaction between an azide (conjugated with the Alexa Fluor
488 fluorophore) and an alkyne (EdU). Briefly, cells incubated
for 30 minutes with the azide conjugate and copper sulphate,
at room temperature, protected from light. Next, the cells
were incubated with ribonuclease A and with the nuclear
dye 7-actinomycin D (7-AAD), widely used as a cell viability
and cell cycle marker, for 30min, EdU incorporation and
7-AAD signal were detected on a BD FACScalibur Flow
Cytometer, using the Cellquest Pro software, version 0.3.efab
(Becton Dickinson, San Jose, CA, USA). Thirty thousand
events were acquired per each experiment in the region of
interest (including apoptotic cells, and G0/G1, S and G2/M
cell cycle phases). Aminimum of 4 independent experiments
was analyzed for each condition. Data were analyzed using
the WinMDI2.9 software and are presented as means ± SEM
of the number of nonapoptotic cells that incorporated EdU
(% of control), as previously described [31].
2.6. Western Blot Analysis. Cells were scraped and lysed
in 50mM Tris-HCl, 0.15M NaCl, 1mM EDTA, 1% Igepal,
and 10% glycerol, supplemented with 200𝜇M phenylmethyl-
sulfonyl fluoride, 1 𝜇g/mL chymostatin, 1𝜇g/mL leupeptin,
1 𝜇g/mL antipain, 1 𝜇g/mL pepstatin A, 1mM sodium ortho-
vanadate, 1𝜇M dithiothreitol, and 5mM NaF, pH 7.5, 4∘C.
Protein concentration was determined by the BCA method
(BCA Protein Assay kit, Pierce, Rockford, IL, USA), accord-
ing to manufacturer’s instructions. 6x concentrated sample
buffer was added and samples were denatured at 95∘C for
5min.Next, samples were used for protein separation by elec-
trophoresis in sodium dodecyl sulfate (SDS)-polyacrylamide
gels using MiniPROTEAN 3 systems (Bio-Rad Laborato-
ries). Equal amounts of protein were separated by elec-
trophoresis, and, then, electrophoretically transferred to the
activated polyvinylidene difluoride membranes. Membranes
were blocked by 1 h incubation, at room temperature, with
Tris-buffered saline (137mMNaCl, 20mM Tris-HCl, pH 7.6)
containing 0.1% Tween-20 (TBS-T) and 3% BSA. Incubations
with the primary antibodies (rabbit phospho-ERK1/2 or
rabbit anti-p27kip1, 1 : 1,000) in TBS-T containing 1% blocking
solution were performed overnight, at 4∘C. Next, the incu-
bation with the appropriated alkaline phosphatase-linked
secondary antibodies (anti-rabbit or anti-mouse, 1 : 20,000
in TBS-T containing 1% blocking solution) was performed
at room temperature, during 1 h. After extensive washing in
TBS-T followed by the incubation of the membranes with
the enhanced chemifluorescence reagent, immunoreactive
bands were visualized in the VersaDoc 3000 imaging system
(Bio-Rad, Hercules, CA, USA). Data were analyzed with the
Quantity One software version 4.6.9 (Bio-Rad Laboratories).
Protein control loadings were either performed after mem-
branes reactivation (5–10 s in 100% methanol and 20min
in TBS-T) using primary antibodies against rabbit ERK1/2
(1 : 1,000) or mouse 𝛼-tubulin (1 : 10,000).
2.7. Determination of cGMP Levels. cGMP levels in cultured
SVZ-derived stem cells were determined after exposure to
drugs for 6 h, using a cGMP Enzyme immunoassay Biotrak
System. This experimental assay is based on competition
between unlabelled cGMP from cell lysates and a fixed
quantity of peroxidase-labelled cGMP, for a limited number
of binding sites on a cGMP specific antibody coated on a 96-
well plate. Cell lysis and cGMPmeasurement were performed
according to manufacturer’s instructions and as previously
described [32]. Optical density was read at 450 nm. All the
experiments were carried out in duplicate. The results are
expressed as femtomoles per million of cells.
2.8. Data Analysis. Data are expressed as means ± SEM.
Statistical significance was determined by using two-tailed 𝑡-
tests or one-factor analysis of variance (ANOVA) followed
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Figure 1: The PDE5 inhibitors T0156, sildenafil, and zaprinast stimulated the proliferation of SVZ neural stem cells following a 6 h or 24 h
exposure. Cells were treatedwith 1 𝜇MT0156 (a), 1𝜇M, 10 𝜇Mand 50 𝜇Msildenafil (b), or 10 𝜇Mand 50 𝜇Mzaprinast (c) for 6 h, andwith 1 𝜇M
T0156 (d), 1𝜇M sildenafil (e), or 10𝜇M zaprinast (f) for 24 h. The incorporation of EdU was assessed by flow cytometry. Data are expressed
as means ± SEM of at least 4 independent experiments. (a), (d), (e), and (f) two-tailed 𝑡-test, ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01, significantly different
from control and, (b) and (c) one-way ANOVA (Dunnett’s post-test), ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01, significantly different from control.
by Bonferroni’s or Dunnett’s post-tests, as appropriate and
indicated in the figure legends. Differences were considered
significant when 𝑃 < 0.05. The software used was GraphPad
Prism 5.0 (GraphPad Software, La Jolla, CA, USA).
3. Results
3.1. Characterization of SVZ Primary Cultures. To investigate
the expression of phosphodiesterases in SVZ-derived neural
stem cell cultures, we assessed the presence of the cGMP-
specific PDE5A, PDE9A, and PDE6C by PCR. Despite PDE6
presence is only described in retina photoreceptors [33], we
also studied its expression in SVZ-derivedNSC cultures since
some of the inhibitors for PDE5 also act on PDE6. The
expression of several PDEs normally found in the brain was
analyzed in SVZ cultures by reverse-transcription PCR. We
studied the presence of the cGMP-specific isoforms, PDE5A,
PDE6C, and PDE9A. We also assessed the expression of
PDE1 (isoforms PDE1A, 1B and 1C), and PDE10A, which
hydrolyze both cAMP and cGMP, as well as the cAMP-
specific PDE7 enzyme isoforms, PDE7A, and PDE7B, whose
presence in the brain is well documented [34–36]. We
observed the presence of PDE1, PDE5, PDE7 and PDE9 in
SVZ cultures, while PDE10 is absent (see Supplementary
Figure 1 in Supplementary materials available online at:
http://dx.doi.org/10.1155/2014/878397). Moreover, expression
of PDE6 catalytic subunit was not detected in SVZ-derived
NSC cultures, but it was detected in the retina.
3.2. Inhibition of PDE5 Increases Cell Proliferation. Neural
stem cell proliferation was evaluated by assessing the incor-
poration of EdU by flow cytometry, following exposure to
PDE5 inhibitors for 6 h. All PDE5 inhibitors increased the
proliferation of SVZ-derived NSC. Treatment with T0156
(1 𝜇M [37]) significantly increased the incorporation of EdU
(140.7 ± 11.9% of the control, 𝑃 < 0.05; Figure 1(a)), when
compared to control cultures (no treatment). Both sildenafil
and zaprinast increased EdU incorporation, in comparison to
untreated cultures, as follows: sildenafil (1 𝜇M, 137.4 ± 7.0%,
𝑃 < 0.05; 10 𝜇M, 120.8 ± 10.4%, 𝑃 > 0.05; 50 𝜇M, 141.3 ±
12.6%, 𝑃 < 0.01; Figure 1(b)) and zaprinast (10 𝜇M, 125.6 ±
7.8%, 𝑃 < 0.01; 50𝜇M, 118.1 ± 5.6%, 𝑃 > 0.05; Figure 1(c)).
According to these data, 1𝜇M sildenafil and 10 𝜇M zaprinast
were selected for all the subsequent experiments.
In order to investigate whether this effect of PDE5 inhib-
itors on SVZ-derived NSC proliferation was maintained for
longer times of exposure, cells were treated for 24 h with
T0156, sildenafil, or zaprinast, and EdU incorporation was
assessed by flow cytometry. The data presented in Figure 1
shows that, following 24 h of treatment, T0156 (1𝜇M; 135.6 ±
7.3% of the control, 𝑃 < 0.01; Figure 1(d)), sildenafil (1 𝜇M;
133.2 ± 8.2%, 𝑃 < 0.05; Figure 1(e)) or zaprinast (10𝜇M;
146.5 ± 13.9%, 𝑃 < 0.05; Figure 1(f)) increased SVZ-derived
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Figure 2: Inhibition of the ERK1/2 pathway prevented proliferation of SVZ cells stimulated by PDE5 inhibitors. Cell proliferation following
treatment with 1 𝜇M U0126 and 1 𝜇M T0156 (a, d), 1𝜇M sildenafil (b, e) or 10𝜇M zaprinast (c, f) was assessed by incorporation of EdU and
evaluated by flow cytometry following 6 h and 24 h of treatment. Data are expressed as means ± SEM of at least 4 independent experiments.
One-way ANOVA (Bonferroni’s post-test), ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001, significantly different from control and +𝑃 < 0.05, and
+++
𝑃 < 0.001, significantly different from the PDE5 inhibitor.
NSC proliferation, in comparison to untreated cultures. The
incorporation of EdU was further assessed by microscopy
analysis. Likewise, following 24 h of treatment, T0156 (1 𝜇M;
182.4 ± 11.8% of the control, 𝑃 < 0.001; Supplementary
Figures 2(a) and 2(b)), sildenafil (1 𝜇M; 157.6 ± 8.9%, 𝑃 <
0.01; Supplementary Figures 2(a) and 2(b)), or zaprinast
(10 𝜇M; 142.1% ± 14.1%, 𝑃 < 0.05; Supplementary Figures
2(a) and 2(b)) increased SVZ-derived NSC proliferation, in
comparison to untreated cultures (100% corresponding to
2.7 ± 0.4% of the total of live cells). Moreover, treatment
with these concentrations of PDE5 inhibitors did not have a
cytotoxic effect on SVZ cultures (Supplementary Table 2), as
evaluated by detection of the nuclear dye signal, 7-AAD, by
flow cytometry.
3.3. PDE5 Inhibition Increases cGMP Levels. To investigate
whether PDE5 inhibition resulted, in fact, in increased
cGMP levels, the levels of cGMP were measured following
exposure to different PDE5 inhibitors. As shown in Table 1,
we observed that cGMP levels were significantly increased
following exposure to T0156 (29.7 ± 4.2 fmol/106 cells, 𝑃 <
0.05), sildenafil (28.8 ± 5.1 fmol/106 cells, 𝑃 < 0.05), or zapri-
nast (33.1± 6.1 fmol/106 cells,𝑃 < 0.01) as compared to cGMP
levels measured in untreated cultures (7.4 ± 0.9 fmol/106
cells).
Table 1: PDE5 inhibitors increased the levels of cGMP in SVZ cells.
Treatment cGMP levels (fmol/106 cells)
Control 7.4 ± 0.9
T0156 29.7 ± 4.2∗
Sildenafil 28.8 ± 5.1∗
Zaprinast 33.1 ± 6.1∗∗
Cells were treated for 6 hwith 1 𝜇MT0156, 1 𝜇Msildenafil, or 10 𝜇Mzaprinast
and then lysed to measure the levels of cGMP. Data are expressed as means ±
SEMof 4 independent experiments. One-way ANOVA (Dunnett’s post-test),
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01, significantly different from control.
3.4. PDE5 Inhibition Stimulates Cell Proliferation via the
ERK/MAPK Pathway. To evaluate the involvement of the
ERK/MAPK pathway on cell proliferation stimulated by
PDE5 inhibition, SVZ-derived NSC cultures were treated
with the MEK1/2 inhibitor, U0126. Exposure to U0126 for
6 h prevented the increased EdU incorporation triggered by
T0156 (109.1 ± 6.6% of the control, 𝑃 < 0.05; Figure 2(a)),
sildenafil (79.5 ± 5.8%, 𝑃 < 0.001; Figure 2(b)), or zaprinast
(94.3 ± 7.4%, 𝑃 < 0.05; Figure 2(c)), keeping cell proliferation
similar to control cultures, in comparison to T0156 (6 h, 140.7
± 11.9%, 𝑃 < 0.01), sildenafil (6 h, 137.4 ± 7.0%, 𝑃 < 0.001),
or zaprinast (6 h, 125.6 ± 7.8%, 𝑃 < 0.05) alone, respectively.
Similar results were obtained following 24 h of treatment.
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Figure 3: T0156 or zaprinast, but not sildenafil, increased ERK1/2 phosphorylation following 2 h of treatment. Phospho-ERK1/2 levels
following treatment with 1 𝜇M T0156 (a), 1𝜇M sildenafil (b), and 10 𝜇M zaprinast (c) for 2 h were assessed by Western blot. Representative
images are shown. Data are expressed as means ± SEM of at least 5 independent experiments. Two-tailed 𝑡-test, ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01,
significantly different from control.
In the presence of U0126, the increase in the incorporation
of EdU by T0156 (102.5 ± 10.7% of the control, 𝑃 < 0.05;
Figure 2(d)), sildenafil (96.7 ± 9.6%, 𝑃 < 0.05; Figure 2(e)),
or zaprinast (107.6% ± 3.4%, 𝑃 < 0.05; Figure 2(f)) was
prevented, comparatively to T0156 (24 h, 135.6 ± 7.3%, 𝑃 <
0.01), sildenafil (24 h, 133.2 ± 8.2%, 𝑃 < 0.05) or zaprinast
(24 h, 146.5 ± 13.9%, 𝑃 < 0.01) alone, respectively.
3.5. PDE5 Inhibition Increases ERK1/2 Phosphorylation. Ex-
posure to NO triggers cell proliferation in SVZ-derived NSC
cultures by activation of ERK1/2 signaling, which can be
monitored by evaluating the phosphorylation of ERK1/2 and
the concomitant decrease in the levels of cyclin-dependent
kinase inhibitor 1, p27Kip1 [5]. p27Kip1 is regulated by p90 RSK
and, once phosphorylated, is translocated to the cytosol, fol-
lowed by ubiquitination and degradation by the proteosome,
allowing progression to S-phase [38].
In order to choose the best time to study the effect of
PDE5 inhibition, or sGC activation, on the levels of phospho-
ERK1/2 and p27Kip1, cultures were exposed to T0156 (1𝜇M;
Supplementary Figure 3(a)), sildenafil (1 𝜇M; Supplementary
Figure 3(b)), zaprinast (10 𝜇M; Supplementary Figure 3(c)),
or YC-1 (20 𝜇M; Supplementary Figure 3(d)) for 30min, 1 h,
or 2 h. Treatment with T0156, zaprinast, and YC-1 increased
ERK1/2 phosphorylation following 2 h of treatment. Further-
more, the cellular levels of p27Kip1 appear to be decreased,
mainly following a 2 h treatment with T0156. According to
these results, an exposure of 2 h to T0156, sildenafil, zaprinast,
or YC-1 was used in these experiments.
Treatment with T0156 (1 𝜇M; 128.5 ± 10.0% of the control,
𝑃 < 0.05; Figure 3(a)) or zaprinast (10𝜇M; 140.0 ± 11.0%, 𝑃 <
0.01; Figure 3(c)) significantly increased ERK1/2 phosphory-
lation in comparison to control cultures. However, treatment
with sildenafil (1𝜇M; 89.9 ± 9.8%, 𝑃 > 0.05; Figure 3(b))
did not increase the levels of phospho-ERK1/2 in relation
to untreated cultures. Since a short period of exposure to
sildenafil (1 𝜇M, for 2 h) did not affect phospho-ERK1/2
levels, we decided to test a longer time of exposure (6 h).
Interestingly, we did not observe any remarkable differences
in phospho-ERK1/2 (106.8 ± 8.5%, 𝑃 > 0.05; Supplementary
Figure 4(a)) following exposure to sildenafil for 6 h, when
compared to control cultures.
3.6. PDE5 Inhibition Enhances Cell Proliferation via sGC/PKG
Pathway. To analyze whether the sGC/PKG pathway is
involved in cell proliferation stimulated by PDE5 inhibition,
SVZ-derivedNSCcultureswere exposed to the sGC inhibitor,
ODQ, or the PKG inhibitor, KT5823. We found that ODQ
prevented cell proliferation stimulated by T0156 (105.5 ± 7.9%
of the control, 𝑃 < 0.05; Figure 4(a)), sildenafil (98.3 ± 9.0%,
𝑃 < 0.001; Figure 4(b)), and zaprinast (101.1± 8.0%,𝑃 < 0.05;
Figure 4(c)), as compared to T0156 (140.7 ± 11.9%, 𝑃 < 0.01),
sildenafil (137.4 ± 7.0%, 𝑃 < 0.001), or zaprinast (125.6 ± 7.8%,
𝑃 < 0.05) alone, respectively. Moreover, following 24 h of
treatment, ODQ is also effective in preventing the increase
of EdU-positive cells by T0156 (109.1 ± 5.5%, 𝑃 < 0.05;
Figure 4(d)), sildenafil (110.8 ± 4.4%, 𝑃 < 0.05, Figure 4(e)),
and zaprinast (105.1 ± 10.8%, 𝑃 < 0.05, Figure 4(f)), in
comparison to T0156 (135.6 ± 7.3%, 𝑃 < 0.01), sildenafil
(24 h, 133.2 ± 8.2%, 𝑃 < 0.001), or zaprinast (146.5 ± 13.9%,
𝑃 < 0.05) alone, respectively.
By inhibiting PKG with KT5823, following 6 h of treat-
ment with PDE5 inhibitors, we observed a prevention of
the increase in cell proliferation induced by T0156 (102.6 ±
7.1% of the control, 𝑃 < 0.05; Figure 5(a)), sildenafil (101.1
± 9.0%, 𝑃 < 0.01; Figure 5(b)), and zaprinast (99.5 ± 7.4%,
𝑃 < 0.05; Figure 5(c)), and cell proliferation became similar
to basal levels, whereas the response to T0156 (6 h, 140.7 ±
11.9%, 𝑃 < 0.01), sildenafil (6 h, 137.4 ± 7.0%, 𝑃 < 0.001) or
zaprinast (6 h, 125.6 ± 7.8%, 𝑃 < 0.05) alone, respectively,
was maintained. Similarly, 24 h of treatment with KT5823
prevented the increase in cell proliferation induced by T0156
(108.5 ± 7.9%, 𝑃 < 0.05; Figure 5(d)), sildenafil (106.8 ± 5.3%,
𝑃 < 0.01; Figure 5(e)), and zaprinast (108.1 ± 4.9%, 𝑃 < 0.01;
Figure 5(f)), in comparison to T0156 (24 h, 135.6 ± 7.3%, 𝑃 <
0.01), sildenafil (24 h, 133.2 ± 8.2%, 𝑃 < 0.001), or zaprinast
(24 h, 146.5 ± 13.9%, 𝑃 < 0.01) alone, respectively.
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Figure 4: Inhibition of sGC prevented the proliferation of SVZ cells stimulated by PDE5 inhibitors. Cell proliferation following treatment
with 50 𝜇MODQ and 1 𝜇MT0156 (a, d), 1𝜇Msildenafil (b, e), or 10 𝜇Mzaprinast (c, f) was assessed by incorporation of EdU and evaluated by
flow cytometry, following 6 h or 24 h treatment. Data are expressed as means ± SEM of at least 5 independent experiments. One-way ANOVA
(Bonferroni’s post-test), ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 and ∗∗∗𝑃 < 0.001, significantly different from control and +𝑃 < 0.05 and +++𝑃 < 0.001
significantly different from the PDE5 inhibitor.
3.7. PKG Is Involved in ERK1/2 Phosphorylation Induced by
PDE5 Inhibition. In order to evaluate whether inhibiting
PKG with KT5823 would antagonize the effect of PDE5
inhibition by T0156 or zaprinast on ERK1/2 phosphorylation,
samples obtained from SVZ-derived NSC cultures were ana-
lyzed by Western blot, following 2 h of treatment. Treatment
with KT5823 suppressed the increase in phospho-ERK1/2
levels induced by T0156 (107.2 ± 6.2% of the control, 𝑃 >
0.05; Figure 6(a)) or zaprinast (110.5 ± 7.9%, 𝑃 > 0.05;
Figure 6(c)) in comparison to T0156 (128.5± 10.0%,𝑃 < 0.05)
and zaprinast (140.0 ± 11.0%, 𝑃 < 0.05) alone, respectively.
On the contrary, as sildenafil did not stimulate ERK1/2
phosphorylation (Figure 3(b)), treatment with KT5823 did
not change phospho-ERK1/2 levels (120.2 ± 11.0%, 𝑃 > 0.05;
Figure 6(b)) when compared to sildenafil alone (89.9 ± 9.8%,
𝑃 > 0.05).
3.8. T0156 Treatment Decreases p27Kip1 Levels. Next, we eval-
uated whether p27Kip1 levels were altered following 2 h of
exposure to T0156, sildenafil, or zaprinast, by Western blot.
We observed that, following treatment with T0156, p27Kip1
levels significantly decreased (80.0 ± 7.2% of the control,
𝑃 < 0.05; Figure 7(a)) in comparison to the levels found in
untreated cultures. On the contrary, treatment with sildenafil
(106.4 ± 6.7%, 𝑃 > 0.05; Figure 7(b)) or zaprinast (97.4 ±
4.8%, 𝑃 > 0.05; Figure 7(c)) did not change p27Kip1 levels
in comparison to control cultures. Moreover, similar to
what was observe for ERK1/2 phosphorylation, following a
longer exposure to sildenafil, for 6 h, we did not observe any
remarkable differences in the levels of p27Kip1 (91.7 ± 8.9%,
𝑃 > 0.05; Supplementary Figure 4(b)), when compared to
control.
In order to test whether this effect can be reversed by
inhibiting the ERK1/2 pathway, NSC cultures were treated
with U0126 for 2 h. By Western blotting, we observed that
U0126 alone increased p27Kip1 levels above the baseline (118.0
± 7.5%; Figure 8). Furthermore, the levels of p27Kip1 were
significantly increased following treatment with U0126 plus
T0156 (123.5 ± 13.0% of the control, 𝑃 < 0.01; Figure 8(a)),
comparatively to T0156 (80.0 ± 7.2%, 𝑃 > 0.05) alone. On
the other hand, U0126 did not change the levels of p27Kip1
in samples treated with sildenafil (99.6 ± 9.6%, 𝑃 > 0.05;
Figure 8(b)) or zaprinast (99.3 ± 4.6%, 𝑃 > 0.05; Figure 8(c))
as compared to sildenafil (106.4± 6.7%,𝑃 > 0.05) or zaprinast
(97.4 ± 4.8%, 𝑃 > 0.05) alone, respectively.
We also observed that inhibition of PKG did not appear
to affect the levels of p27Kip1 following treatment with T0156
(84.1 ± 10.2%, 𝑃 > 0.05; Figure 9(a)), sildenafil (96.3 ± 7.8%,
𝑃 > 0.05; Figure 9(b)), or zaprinast (105.1 ± 10.0%, 𝑃 > 0.05;
Figure 9(c)), in comparison to T0156 (80.0 ± 7.2%, 𝑃 < 0.05),
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Figure 5: Inhibition of PKG prevented the proliferation of SVZ cells stimulated by PDE5 inhibitors. Cell proliferation following treatment
with 1 𝜇MKT5823 and 1 𝜇MT0156 (a, d), 1𝜇M sildenafil (b, e), or 10𝜇M zaprinast (c, f) was assessed by incorporation of EdU and evaluated
by flow cytometry, following 6 h or 24 h of treatment. Data are expressed as means ± SEM of at least 4 independent experiments. One-way
ANOVA (Bonferroni’s post-test), ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 and ∗∗∗𝑃 < 0.001, significantly different from control and +𝑃 < 0.05 and ++𝑃 < 0.01
significantly different from the PDE5 inhibitor.
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Figure 6: Inhibition of PKG prevented the phosphorylation of ERK1/2 by treatment with T0156 or zaprinast. Levels of phospho-ERK1/2
following treatment with 1𝜇MKT5823 and 1 𝜇MT0156 (a), 1𝜇M sildenafil (b), and 10 𝜇M zaprinast (c) for 2 h were assessed byWestern blot.
Representative images are shown. Data are expressed as means ± SEM of at least 4 independent experiments. One-way ANOVA (Bonferroni’s
post-test), ∗𝑃 < 0.05, significantly different from control.
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Figure 7: Treatment with T0156 decreased p27Kip1 levels. p27Kip1 levels following treatment 1 𝜇M T0156 (a), 1𝜇M sildenafil (b), or 10 𝜇M
zaprinast (c) for 2 h were assessed by Western blot. Representative images are shown. Data are expressed as means ± SEM of at least 6
independent experiments. Two-tailed 𝑡-test, ∗𝑃 < 0.05, significantly different from control.
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Figure 8: Inhibition of MAPK pathway prevented the decrease of p27Kip1 levels mediated by T0156. p27Kip1 levels following treatment with
1 𝜇M U0126 and 1 𝜇M T0156 (a), 1𝜇M sildenafil (b), or 10 𝜇M zaprinast (c) for 2 h were assessed by Western blot. Representative images are
shown. Data are expressed as means ± SEM of at least 5 independent experiments. One-way ANOVA (Bonferroni’s post-test), ∗𝑃 < 0.05,
significantly different from control and ++𝑃 < 0.01, significantly different from T0156.
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Figure 9: Inhibition of PKG did not prevent the decrease of p27Kip1 levels by T0156. p27Kip1 levels following treatment with 1 𝜇M KT5823
and 1 𝜇M T0156 (a), 1𝜇M sildenafil (b), or 10 𝜇M zaprinast (c) for 2 h were assessed by Western blot. Representative images are shown. Data
are expressed as means ± SEM of at least 4 independent experiments. One-way ANOVA (Bonferroni’s post-test), ∗𝑃 < 0.05, significantly
different from control.
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Figure 10: Activation of sGC stimulates proliferation of NSC, increases ERK1/2 phosphorylation, and decreases p27Kip1 levels. Cell
proliferation following treatment with 20 𝜇M YC-1 (a) for 24 h was assessed by the incorporation of EdU and analyzed by flow cytometry.
Levels of phospho-ERK1/2 following treatment with 20 𝜇M YC-1 (b) or YC-1 plus 1 𝜇M KT5823 (c) and p27Kip1 levels following treatment
with YC-1 (d) or YC-1 plus 1𝜇M U0126 (e) or KT5823 (f) for 2 h were assessed by Western blot. Representative images are shown. Data are
expressed as means ± SEM of at least 4 independent experiments. (a), (b), and (d) two-tailed 𝑡-test, ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01, significantly
different from control and (c), (e), and (f) one-way ANOVA (Bonferroni’s post-test), +𝑃 < 0.05, significantly different from YC-1.
sildenafil (106.4 ± 6.7%, 𝑃 > 0.05), or zaprinast (97.4 ± 4.8%,
𝑃 > 0.05) alone, respectively.
3.9. YC-1 Stimulates Cell Proliferation via the sGC/PKG and
ERK/MAPK Pathways. To evaluate the effect on the prolif-
eration of NSC of increasing the levels of cGMP, by direct
activation of sGC, SVZ-derived NSC cultures were treated
with the sGC activator, YC-1 (20𝜇M). EdU incorporation
was assessed by flow cytometry and microscopy analysis.
Exposure to YC-1, for 24 h, increased the incorporation of
EdU by NSC (137.1 ± 6.8% of the control, 𝑃 < 0.01;
Figure 10(a)), when compared to untreated cultures, as eval-
uated by flow cytometry. Similarly, evaluating EdU labeling
by microscopy, the increase in cell proliferation following
24 h of treatment with YC-1 was also observed (145.8 ±
12.6%, 𝑃 < 0.05; Supplementary Figures 2(a) and 2(c)), in
comparison to untreated cultures. Treatment with the same
concentration of YC-1 for 6 h did not alter the percentage of
EdU-positive cells in comparison to control cultures (data not
shown). Furthermore, treatmentwith the cGMP-analogue, 8-
Br-cGMP, also increased proliferation ofNSC (20 𝜇M; 145.9±
11.9%, 𝑃 < 0.05; Supplementary Figures 2(a) and 2(d)), when
compared to control cultures.
In order to evaluate whether direct activation of sGC
would also affect phosphorylation of ERK1/2 and p27Kip1
levels, samples obtained from SVZ-derived NSC cultures
were treated with the sGC activator. ERK1/2 phosphorylation
and p27Kip1 levels were analyzed by Western blot, following
2 h of treatment. In fact, treatment with YC-1 significantly
increased ERK1/2 phosphorylation (123.3 ± 8.9%, 𝑃 < 0.05;
Figure 10(b)), in comparison to control cultures. Moreover,
inhibition of PKG with KT5823 prevented the increase in
phospho-ERK1/2 levels due to exposure to YC-1 (85.6 ±
10.4%, 𝑃 < 0.05; Figure 10(c)) when compared to YC-1 alone
(123.3 ± 8.9%, 𝑃 > 0.05).
Furthermore, similar to T0156, the levels of p27Kip1 were
significantly decreased following treatment with YC-1 (77.5 ±
9.0%, 𝑃 < 0.05, Figure 10(d)), when compared to untreated
cultures. This effect can be reversed by inhibiting the ERK1/2
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pathway,withU0126, as the levels of p27Kip1 were significantly
increased following treatment with U0126 plus YC-1 (114.9 ±
3.4%, 𝑃 < 0.05; Figure 10(e)), comparatively to YC-1 (77.5
± 9.0%, 𝑃 > 0.05) alone. Inhibition of PKG also appeared
to prevent the decrease in p27Kip1 levels induced by YC-1,
as treatment with KT5823 and YC-1 tended to raise p27Kip1
levels close to basal (104.5 ± 11.3%, 𝑃 > 0.05; Figure 10(f))
when compared to YC-1 alone (77.5 ± 9.0%, 𝑃 > 0.05).
4. Discussion
In this work, we show that proliferation of NSC is stim-
ulated by cGMP, since inhibition of cGMP hydrolysis by
PDE5 enhances the proliferation of NSC isolated from SVZ.
Moreover, direct activation of sGC by the activator YC-1 has
a similar effect in increasing NSC proliferation following 24 h
of treatment.We also show that ERK1/2 is activated following
treatmentwith PDE5 inhibitors (except sildenafil), suggesting
the involvement of this pathway in cell proliferationmediated
by PDE5 inhibition. Taken together, our data point out
to the activation by PDE5 inhibition in SVZ cells of two
pathways: the sGC/PKG and the ERK/MAPK pathways, the
same pathways responsible for the proliferative effect of NO
[9].
Using inhibitors with different selectivity for PDE5 we
show that inhibition of PDE5 either with T0156, sildenafil,
or zaprinast enhances the proliferation of NSC, the first
step of neurogenesis. This is the first study comparing the
proliferative potential of different PDE5 inhibitors on NSC.
Several studies report the proneurogenic effect of sildenafil
on SVZ cultures [39] as in animal models of brain injury [24–
26], but the effect of sildenafil on neurogenesis was never
compared to other PDE5 inhibitors. We show a significant
increase in the levels of cGMP in NSC treated with PDE5
inhibitors, which is responsible for the increase in cell
proliferation. Moreover, direct activation of sGC with YC-
1, and, thus, increasing in cGMP production, also enhances
NSC proliferation upon 24 h of treatment. Likewise, a cGMP
analogue, 8-Br-cGMP, also enhances SVZ cell proliferation,
as shown in this work and previously by our group [9].
Here, we show that, inhibiting the MAPK pathway, the
proliferative effect of PDE5 inhibitors is abolished in both
short- and long-term exposures, which is in agreement with
the established contribution of ERK pathway to the prolif-
eration of NSC [5]. In addition, cell proliferation induced
by the PDE5 inhibitors was also prevented by inhibitors of
sGC (ODQ) or PKG (KT5823), showing the involvement of
sGC/PKG pathway. We have previously shown that both NO
and cGMP analogues enhance SVZ proliferation by a mech-
anism that is dependent on activation of PKG, concomitantly
with ERK activation [9]. The present study suggests that the
same pathways involved in stimulating cell proliferation by
the endogenousmessenger (NO) are also being stimulated by
blocking the hydrolysis of cGMP with PDE5 inhibitors.
T0156 and zaprinast were able to activate ERK1/2, an
effect that is prevented by inhibition of PKG, suggesting
that ERK1/2 activation is dependent on the cGMP effector
kinase, PKG. Several other studies report the regulation of
ERK1/2 activation by PKG, which is involved in multiple
cell functions [9, 40–42]. Furthermore, treatment with T0156
decreases the levels of the cyclin-dependent kinase inhibitor
1, p27Kip1. p27Kip1 prevents progression from G1 to S-phase,
being a key regulator of cell division of neural progenitor cells
[43, 44]. The downregulation of p27Kip1 levels by T0156 is
consistent with the increase in cell proliferation and ERK1/2
phosphorylation shown above. In agreement with this, we
found that blockade of ERK/MAPK pathway, by inhibition
of MAPK, is able to prevent this effect. Moreover, direct
activation of sGC by YC-1 has a similar effect to that of
T0156 in increasing phospho-ERK1/2 and decreasing p27Kip1
levels, similar to those previously described with NO or
the cGMP analogue, 8-Br-cGMP [9]. However, although
zaprinast increases ERK1/2 phosphorylation, it does not
appear to affect the levels of p27Kip1. In fact, by the lack
of selectivity of zaprinast for PDE5, we cannot exclude the
possibility that this inhibitor could interact with other PDE
and, thus, to activate other pathways, than the two studied
here.
Interestingly, while sildenafil increased NSC prolifera-
tion, it neither increased ERK1/2 phosphorylation nor altered
the levels of p27Kip1 for any of the times tested in this
work. Even though ERK1/2 is not phosphorylated follow-
ing treatment with sildenafil, we observed that the MAPK
inhibitor, U0126, completely blocks sildenafil-enhanced cell
proliferation, which suggests the involvement of other sig-
naling pathways in the proliferative effect of this drug. A
similar lack of effect of sildenafil on ERK1/2 phosphorylation
has already been described by Wang and colleagues [39].
According to that study, sildenafil (300 nM) does not increase
ERK1/2 phosphorylation following 1 h of treatment [39].
These authors suggest that the increase in cGMP levels
via inhibition of PDE5 activity enhances neurogenesis in
the SVZ through the PI3-K/Akt pathway [39]. Within this
scenario, sildenafil appears to act in a proliferative pathway
different from the one activated by NO, by cGMP analogues
[9], and by the other PDE5 inhibitors used in this study.
Thus, understanding the pathways activated by sildenafil is
important in order to understand its possible value in the field
of proneurogenic therapies.
Therapies involving the specific inhibition of PDE5 are
being evaluated for the treatment of several neurological
conditions. Regarding the possible enhancement of endoge-
nous neurogenesis by this strategy, our study helps in better
understanding the initial events that promote proliferation of
NSC in the initial stages of neurogenesis by PDE5 inhibition.
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